Seamless Therapeutics Showcases Innovative Gene Editing Data
Today, Seamless Therapeutics announced its plans to present groundbreaking preclinical data at a key congress. This data emphasizes its unique capabilities in reprogramming large serine recombinases (LSRs) to target specific sites in the human genome effectively. The company's pioneering recombinases have been engineered to perform intricate functions, such as excising, exchanging, inverting, or even inserting gene-sized segments of DNA precisely where needed, unshackling researchers from depending solely on the cell's inherent DNA repair pathways.
Significant Advances in Recombinase Technology
Seamless Therapeutics is also set to reveal new findings on its engineered zinc-finger dependent recombinases. These innovations demonstrate the company’s capability to condition the activity of its recombinases for LSRs and tyrosine recombinases (Y-SSRs), showing versatility in its applications. Such advancements in technology position Seamless at the forefront of next-generation gene editing, essential for creating effective therapeutics.
Insights from the CEO
Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics, shared that the upcoming data presentation at the congress highlights an exciting new phase in their research. He stated, "Our findings validate our innovative approach, positioning us as leaders in the gene editing landscape for developing new therapeutic solutions. By programming recombinases that can recognize user-defined sequences, we eliminate the need for pre-existing target sites, streamlining DNA integration processes significantly." This evolution signifies the company’s commitment to bridging the gap between research and clinical applications.
Presentation Details and Poster Sessions
During the European Society of Gene & Cell Therapy Congress, taking place from October 22 to 25, the company will present two key posters that highlight its cutting-edge technologies. The first presentation, titled "P0670 - Reprogramming Large Serine Recombinases for Site-Specific Integration into Mammalian Genomes," will occur on Thursday, October 24, from 6:00 to 7:30 pm CEST. Dr. Teresa Rojo-Romanos, the Co-founder and Head of Technology & Platform Development, will lead this session.
Enhancements in Target Site Recognition
The company’s proprietary search motif techniques assist in identifying ideal target sites across nearly all coding genes, as well as potential safe harbor sites in human DNA. Through creative directed evolution and rational design strategies, Seamless engineers its LSRs to function effectively at four selected natural target sites within the human genome. This exciting research shows that these engineered LSR clones exhibit high efficiency in bacterial systems and translate their capabilities well into human cell scenarios. For instance, the engineered LSR, known as IntSTX-SH2, illustrated notable success, integrating DNA sequences precisely into the specific SH2 locus.
Optimizing Gene Integration Techniques
Furthermore, the latest optimizations led to the development of IntSTX-SH2 2.0. This enhanced variant demonstrated a remarkable three-fold increase in activity compared to its predecessor. This advancement illustrates Seamless’ potential for even higher efficiency and precision in gene editing, propelling their work into in vivo studies aimed at utilizing the liver as a production site for necessary metabolic enzymes.
Exploring Zinc-Finger Dependent Recombinases
Another significant contribution to be presented is focused on zinc-finger dependent recombinases. Titled "P0590 - Zinc-Finger Dependent Recombinases for Precision Genome Editing," this session will also unfold on October 24, managed by Sr. Scientist Liliya Mukhametzyanova. The findings highlight the identification of insertion sites for zinc-finger binding domains within Y-SSRs and LSRs, opening doors for new opportunities in genome editing. The approach guarantees that gene editing occurs only at predefined sites through innovative design.
About Seamless Therapeutics
Seamless Therapeutics is committed to transforming the gene editing paradigm. By leveraging its proprietary technologies, the company seeks to address significant medical challenges impacting patients with severe health conditions. Their platform not only allows reprogramming of recombinases but also actively cultivates a promising field of therapeutic candidates to manage a variety of diseases.
Frequently Asked Questions
What type of data is Seamless Therapeutics presenting at the congress?
Seamless Therapeutics will showcase preclinical data on large serine recombinases and zinc-finger dependent recombinases, emphasizing their capabilities in precise DNA editing.
Who is leading the presentations for Seamless Therapeutics?
The presentations will be led by Dr. Teresa Rojo-Romanos and Sr. Scientist Liliya Mukhametzyanova, highlighting different technological advancements.
What is the significance of the engineered LSRs created by Seamless?
The engineered LSRs can precisely integrate DNA fragments into specific loci, allowing unprecedented accuracy in genetic modifications.
What are the company’s long-term goals for this technology?
Seamless Therapeutics aims to translate their innovative findings into clinical applications to address high unmet medical needs with novel therapeutics.
How does Seamless Therapeutics’ approach differ from traditional gene editing?
Their method bypasses the need for predefined target sites and offers seamless, efficient DNA integration, enhancing the versatility of gene editing strategies.
